Results 191 to 200 of about 37,077 (282)

Identification of Extracellular Vesicle Signatures of Daratumumab Treated Multiple Myeloma

Journal of Extracellular Vesicles, Volume 15, Issue 2, February 2026.
Multiple myeloma peripheral blood extracellular vesicles (EVs) are a source of non‐invasive biomarkers with potential for routine monitoring and to complement or replace invasive bone marrow biopsy. In this study, five proteins were significantly different from healthy controls and three associated with long‐term response on Daratumumab which may have ...
Kieran Brennan, Katrine F. Iversen, Alfonso Blanco‐Fernández, Thomas Lund, Torben Plesner, Margaret M. Mc Gee   +5 more
wiley   +1 more source

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. [PDF]

Front Immunol
Frontiers Production Office.
europepmc   +1 more source

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Polatuzumab vedotin (Pola) is an antibody‐drug conjugate approved for the treatment of diffuse large B‐cell lymphoma (DLBCL). Several reports suggest that the tumor microenvironment influences the outcome of DLBCL treatments; with Pola, however, the link between tumor microenvironment and treatment outcome remains unclear ...
Mayu Tomita, Natsumi Kawasaki, Keigo Yorozu, Sei Shu, Chie Kato, Mitsue Kurasawa, Bansho Masutani, Nicolas Sax, Yoriko Yamashita‐Kashima, Shigeki Yoshiura   +9 more
wiley   +1 more source

Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements. [PDF]

J Clin Invest
DiNapoli SR, Wright KM, Mog BJ, Pearlman AH, Nichakawade TD, Marcou N, Hsiue EH, Hwang MS, Douglass J, Liu Q, Watson E, Dal Molin M, Cohen JD, Popoli M, Paul S, Konig MF, Wyhs N, Azurmendi PA, Glavaris S, Ge J, Awosika TO, Liu J, Gabrielson KL, Gabelli SB, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Zhou S, Vogelstein B.   +29 more
europepmc   +1 more source

Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Introduction Real‐world data on teclistamab in relapsed or refractory multiple myeloma (R/R MM), particularly in elderly patients, remain limited. Methods We analysed efficacy and safety outcomes in patients ≥ 75 years from the French RetrosTECtive cohort.
A. Coste, S. Godet, S. Manier, J. R. Eveillard, C. Croizier, C. Mariette, C. Breal, H. Manjra, C. Touzeau, M. Mohty, R. Belkhir, A. Bobin, A. Lévêque, B. Cherel, L. Montes, F. Orsini‐Piocelle, L. Frenzel, D. Robu, E. Chalayer, S. Harel, L. Vincent, L. Bauschert, A. Dony, R. Tabrizi, P. Moreau, C. Hulin, A. Perrot   +26 more
wiley   +1 more source

Bone Formation and the Wnt Signaling Pathway. [PDF]

, 2016
Baron, R., Gori, F., Superti-Furga, A.
core   +1 more source

Durable Response to Glofitamab in HIV‐Positive Refractory Burkitt Lymphoma: Case Report and Discussion

eJHaem, Volume 7, Issue 1, February 2026.
ABSTRACT Background Refractory Burkitt lymphoma (BL) has a dismal prognosis after failure of frontline therapy. New treatment options are urgently needed. Methods We describe a 60‐year‐old HIV‐positive patient with refractory and secondary primary BL after frontline and salvage therapy failure, treated off‐label with glofitamab successfully.
Bozzotto Elisa, Magnes Theresa, Kiem Dominik, Zellinger Barbara, Neureiter Daniel, Beer Arno, Egle Alexander, Melchardt Thomas   +7 more
wiley   +1 more source

A review of targeted drug delivery with antibody-drug complexes. [PDF]

J Pharmacol Exp Ther
Sanjanwala D, Meng Y, Guo Z, Bordeau B.
europepmc   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo, Kang‐Jing Xue, Liao Wang, Gang‐Gang Wang, Ting‐Ting Zhang, Shu‐Ling Hou   +5 more
wiley   +1 more source

Modular generation of multispecific antibodies using protein trans-splicing. [PDF]

MAbs
Shadish JA, Bagert JD, Lee AN, Sharp KK, Yang C, Li Y, Wang R, Shin S, Malik AA, Lin J, Huang F, Liu W, Mazor Y.   +12 more
europepmc   +1 more source